The Luxembourg Centre for Systems Biomedicine (LCSB) of the University of Luxembourg is coordinating an EU project for research into new active compounds against Parkinson’s disease (PD). SysMedPD (Systems Medicine of Mitochondrial Parkinson’s Disease) is the name of the project that just started with the involvement of five universities and three companies from Luxembourg, Germany, Ireland, the Netherlands and UK. The European Union is funding the researchers of this consortium with a total of 5.9 million euros.
With this funding, they will be developing novel techniques by which to identify and research into active compounds against PD. They will furthermore be advancing drug candidates towards their medical application.
“Universities and biopharmaceutical companies complement each other’s expertise ideally in SysMedPD,” says Prof. Rudi Balling, LCSB director and coordinator of SysMedPD. “This creates optimal conditions in which to progress a good deal further in developing diagnoses and therapies for Parkinson’s disease.”
Parkinson’s disease is a gradually progressive disease of human nerve tissue, resulting among other things in muscle tremors and muscle rigidity. The mitochondria of nerve cells are often causally involved in the onset – mitochondria being the power plants of cells, in which biochemical reactions provide energy for cellular metabolic processes.
“We estimate that in about ten to twenty percent of all Parkinson’s patients, their mitochondria do not function properly,” says senior LCSB scientist Dr Ronan Fleming, who is significantly involved in the conception and coordination of SysMedPD. “In order to better diagnose, heal or at least effectively curb the progression of Parkinson’s disease, we must understand this dysfunction of mitochondria in detail.”
The researchers within SysMedPD are first concentrating on such patterns of PD in which the mitochondria are damaged by mutations in individual genes. “Later, the results can then be carried over to patient groups in which multiple genes and environmental factors are involved in the onset of PD,” adds Dr Fleming.
The SysMedPD consortium will tackle this task with different approaches: “At the LCSB, we place emphasis on developing new, computational models by which we can better depict the processes going on inside mitochondria,” Ronan Fleming says. Prof. Jens Schwamborn, head of the LCSB group Development and Cell Biology, describes a complementary approach: “We must verify any computational predictions using experiments. Therefore, in the scope of this EU project, we will also employ advanced cellular models, where skin samples obtained from Parkinson’s disease patients are reprogrammed into living human nerve cells.”
To ensure the research results obtained within SysMedPD are translated into application as quickly as possible, the consortium also has biopharmaceutical companies on board. Their areas of involvement are test development for new active compounds and identification of active compounds.
“The project is organised such that the insights that we and the other academic partners gain will complement those of the companies involved very well,” says Prof. Rudi Balling. “With this close connection between public and private research, we can ensure the EU funding, firstly, is employed optimally in the interest of the PD patients and, secondly, will generate economic stimuli. These are important objectives of the EU that we will fulfil here.”
The SysMedPD partners:
- Germany: University of Lübeck (Prof. Christine Klein), EURICE – European Research and Project Office GmbH (Corinna Hahn)
- Ireland: Maynooth University (Dr Niall Finnerty)
- Luxembourg: University of Luxembourg (Prof. Rudi Balling, Dr Ronan Fleming, Prof. Jens Schwamborn)
- Netherlands: Leiden University (Prof. Thomas Hankemeier), Khondrion BV (Prof. Jan Smeitink), Mimetas BV (Dr Paul Vulto)
- Great Britain: University College London (Prof. Anthony Schapira)
http://www.uni.lu/lcsb - Homepage of the Luxembourg Centre for Systems Biomedicine
Britta Schlüter | Universität Luxemburg - Université du Luxembourg
On track to heal leukaemia
18.01.2017 | Universitätsspital Bern
Penn vet research identifies new target for taming Ebola
12.01.2017 | University of Pennsylvania
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).
Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...
10.01.2017 | Event News
09.01.2017 | Event News
05.01.2017 | Event News
18.01.2017 | Power and Electrical Engineering
18.01.2017 | Materials Sciences
18.01.2017 | Life Sciences